AVAN » Topics » Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

These excerpts taken from the AVAN 10-K filed Mar 18, 2008.

Item 5.    MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

        Our common stock began trading on the Nasdaq National Market (the "Nasdaq") under the symbol "AVAN" on August 24, 1998. Prior to that date, we were traded on the Nasdaq under the symbol "TCEL". Our common stock will continue to trade under the symbol "AVAND" for 20 trading days starting March 10, 2008 to designate that it is trading on a post-reverse stock split basis, and will resume trading under the symbol "AVAN" on the NASDAQ Global market after the 20-day period expires on April 7, 2008. The following table sets forth for the periods indicated the high and low closing sales prices for our common stock as reported by NASDAQ. The numbers below do not reflect the 1-for-12 reverse stock split effected on March 7, 2008.

Fiscal Period

  High
  Low
Year Ended December 31, 2006            
  1Q (Jan. 1—March 31, 2006)   $ 2.54   $ 1.66
  2Q (April 1—June 30, 2006)     2.30     1.46
  3Q (July 1—Sept. 30, 2006)     1.65     1.27
  4Q (Oct. 1—Dec. 31, 2006)     1.62     1.29
Year Ended December 31, 2007            
  1Q (Jan. 1—March 31, 2007)   $ 1.55   $ 1.30
  2Q (April 1—June 30, 2007)     1.48     0.74
  3Q (July 1—Sept. 30, 2007)     0.93     0.43
  4Q (Oct. 1—Dec. 31, 2007)     0.70     0.41

        As of March 3, 2008, there were approximately 654 shareholders of our common stock. The price of the common stock was $0.72 as of the close of the market on March 3, 2008. We have not paid any dividends on our common stock since our inception and do not intend to pay any dividends in the foreseeable future. Declaration of dividends will depend, among other things, upon our operating and future earnings, our capital requirements and general business conditions.

36


        The graph below compares the cumulative total stockholder return on the common stock for the period from December 31, 2002 through December 31, 2007, with the cumulative return on (i) NASDAQ Market Index—U.S. Companies and (ii) NASDAQ Pharmaceutical Index. The comparison assumes investment of $100 on December 31, 2002 in our common stock and in each of the indices and, in each case, assumes reinvestment of all dividends.


AVANT IMMUNOTHEAPEUTICS, INC., NASDAQ MARKETINDEX-U.S. AND
PEER GROUP INDICES

         GRAPHIC

 
  12/31/02
  12/31/03
  12/31/04
  12/30/05
  12/29/06
  12/31/07
AVANT Immunotherapeutics, Inc.    $ 100   $ 241   $ 177   $ 166   $ 118   $ 44
Nasdaq Stock Market (U.S.) Index   $ 100   $ 150   $ 163   $ 166   $ 183   $ 198
Nasdaq Pharmaceutical Stock Index   $ 100   $ 147   $ 156   $ 172   $ 168   $ 177

        See Item 11 for information regarding our equity compensation plan.

37




Item 5.    MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES



        Our common stock began trading on the Nasdaq National Market (the "Nasdaq") under the symbol "AVAN" on August 24, 1998. Prior to that date, we were traded
on the Nasdaq under the symbol "TCEL". Our common stock will continue to trade under the symbol "AVAND" for 20 trading days starting March 10, 2008 to designate that it is
trading on a post-reverse stock split basis, and will resume trading under the symbol "AVAN" on the NASDAQ Global market after the 20-day period expires on April 7,
2008. The following table sets forth for the periods indicated the high and low closing sales prices for our common stock as reported by NASDAQ. The numbers below do not reflect the 1-for-12 reverse
stock split effected on March 7, 2008.














































































































Fiscal Period

 High
 Low
Year Ended December 31, 2006      
 1Q (Jan. 1—March 31, 2006) $2.54 $1.66
 2Q (April 1—June 30, 2006)  2.30  1.46
 3Q (July 1—Sept. 30, 2006)  1.65  1.27
 4Q (Oct. 1—Dec. 31, 2006)  1.62  1.29
Year Ended December 31, 2007      
 1Q (Jan. 1—March 31, 2007) $1.55 $1.30
 2Q (April 1—June 30, 2007)  1.48  0.74
 3Q (July 1—Sept. 30, 2007)  0.93  0.43
 4Q (Oct. 1—Dec. 31, 2007)  0.70  0.41




        As
of March 3, 2008, there were approximately 654 shareholders of our common stock. The price of the common stock was $0.72 as of the close of the market on March 3, 2008.
We have not paid any dividends on our common stock since our inception and do not intend to pay any dividends in the foreseeable future. Declaration of dividends will depend, among other things, upon
our operating and future earnings, our capital requirements and general business conditions.



36









NAME="page_dk71701_1_37">















        The graph below compares the cumulative total stockholder return on the common stock for the period from December 31, 2002 through December 31, 2007, with the cumulative
return on (i) NASDAQ Market Index—U.S. Companies and (ii) NASDAQ Pharmaceutical Index. The comparison assumes investment of $100 on December 31, 2002 in our common
stock and in each of the indices and, in each case, assumes reinvestment of all dividends.



NAME="dk71701_avant_immunotheapeutics,_inc.,__ava02793">


AVANT IMMUNOTHEAPEUTICS, INC., NASDAQ MARKETINDEX-U.S. AND
PEER GROUP INDICES



        
GRAPHIC



















































































 
 12/31/02
 12/31/03
 12/31/04
 12/30/05
 12/29/06
 12/31/07
AVANT Immunotherapeutics, Inc.  $100 $241 $177 $166 $118 $44
Nasdaq Stock Market (U.S.) Index $100 $150 $163 $166 $183 $198
Nasdaq Pharmaceutical Stock Index $100 $147 $156 $172 $168 $177




        See
Item 11 for information regarding our equity compensation plan.



37









EXCERPTS ON THIS PAGE:

10-K (2 sections)
Mar 18, 2008

RELATED TOPICS for AVAN:

"Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES" elsewhere:

Avigen (AVGN)
BIOCLINICA INC (BITI)
BioSphere Medical (BSMD)
CollaGenex Pharmaceuticals (CGPI)
PC GROUP, INC. (GAIT)
Lipid Sciences (LIPD)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki